论文部分内容阅读
目的:探讨阿仑膦酸钠对糖尿病合并骨质疏松治疗的临床疗效。方法:2014年3月2016年3月,东莞市大岭山镇社区卫生服务中心糖尿病合并骨质疏松患者186例,随机分组为观察组、对照组,对照组给予常规治疗,观察组口服阿仑膦酸钠,观察组两组患者的骨密度改善程度、症状积分、临床疗效。结果:与治疗前(–1.98±0.51)比较,对照组患者治疗后1年(–1.88±0.51)、治疗后2年(–1.80±0.51)的骨密度明显得到改善,差异具有统计学意义(P<0.05);与对照组治疗后1年、2年后比较,观察组治疗后1年、2年骨密度明显增加,差异具有统计学意义(P<0.05)。与治疗前(19.98±4.81)比较,观察组患者治疗后1年(12.08±3.88)、治疗后2年的症状积分(9.00±3.80)明显得到减少,差异具有统计学意义(P<0.05);与对照组治疗后1年、2年比较,观察组治疗后1年、2年症状积分明显更少,差异具有统计学意义(P<0.05)。对照组治疗有效率为64.52%,观察组治疗有效率为96.77%,观察组明显高于对照组,差异具有统计学意义(P<0.05)。观察组和对照组治疗前后谷丙转氨酶、尿素氮、肌酐水平比较,差异均无统计学意义(P>0.05)。结论:阿仑膦酸钠对糖尿病合并骨质疏松治疗的临床疗效显著,可有效的改善患者的骨质疏松症状,提高骨密度水平,并且对肝肾功能负面作用较低。
Objective: To investigate the clinical efficacy of alendronate in the treatment of diabetic patients with osteoporosis. METHODS: In March 2014, 186 patients with diabetes mellitus and osteoporosis in Dalingshan Town Community Health Center of Dongguan City were randomly divided into observation group, control group and control group. The patients in observation group were given oral alendronate Sodium phosphonate, observation group two groups of patients to improve the degree of bone mineral density, symptom score, clinical efficacy. Results: Compared with the pretreatment (-1.98 ± 0.51), the BMD of the control group was significantly improved at 1 year (-1.88 ± 0.51) and 2 years (-1.80 ± 0.51) after treatment, the difference was statistically significant ( P <0.05). Compared with the control group at 1 year and 2 years after treatment, the bone mineral density in the observation group increased significantly at 1 year and 2 years after treatment, with statistical significance (P <0.05). Compared with that before treatment (19.98 ± 4.81), symptom score (9.00 ± 3.80) in observation group at 1 year after treatment (12.08 ± 3.88) and after 2 years treatment was significantly reduced (P <0.05). Compared with the control group one year and two years after treatment, the symptom scores of the observation group were significantly less after one year and two years after the treatment, the difference was statistically significant (P <0.05). The effective rate of the control group was 64.52%, the effective rate of the observation group was 96.77%, the observation group was significantly higher than the control group, the difference was statistically significant (P <0.05). The levels of ALT, urea nitrogen and creatinine in the observation group and the control group before and after treatment showed no significant difference (P> 0.05). Conclusion: Alendronate has significant clinical efficacy in the treatment of diabetes mellitus combined with osteoporosis. It can effectively improve the patients’ osteoporosis symptoms, increase the bone mineral density, and have a low negative effect on liver and kidney function.